{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=45",
    "query": {
      "intervention": "Placebo Administration first",
      "page": 45
    },
    "page_size": 10
  },
  "pagination": {
    "page": 45,
    "page_size": 10,
    "total_count": 1738,
    "total_pages": 174,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=46&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=44&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T23:45:43.934Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05656534",
      "title": "Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Suvorexant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 81,
      "start_date": "2022-11-29",
      "completion_date": "2024-08-01",
      "has_results": true,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-11-19T23:45:43.934Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05656534"
    },
    {
      "nct_id": "NCT04731922",
      "title": "A Study of TAK-510 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "TAK-510",
          "type": "DRUG"
        },
        {
          "name": "TAK-510 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 124,
      "start_date": "2021-02-03",
      "completion_date": "2022-07-24",
      "has_results": true,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-11-19T23:45:43.934Z",
      "location_count": 2,
      "location_summary": "Las Vegas, Nevada • Austin, Texas",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04731922"
    },
    {
      "nct_id": "NCT02326272",
      "title": "A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis",
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma S.P.R.L.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 227,
      "start_date": "2014-12-15",
      "completion_date": "2018-09-12",
      "has_results": true,
      "last_update_posted_date": "2019-10-03",
      "last_synced_at": "2026-11-19T23:45:43.934Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        },
        {
          "city": "Portsmouth",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02326272"
    },
    {
      "nct_id": "NCT00517075",
      "title": "Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Transcranial Magnetic Stimulation (TMS)",
          "type": "DEVICE"
        },
        {
          "name": "repetitive transcranial magnetic stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 14,
      "start_date": "2004-09",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-11-19T23:45:43.934Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00517075"
    },
    {
      "nct_id": "NCT04172441",
      "title": "Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Congenital Hyperinsulinism"
      ],
      "interventions": [
        {
          "name": "dasiglucagon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zealand Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "364 Days",
        "sex": "ALL",
        "summary": "7 Days to 364 Days"
      },
      "enrollment_count": 12,
      "start_date": "2020-06-19",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-11-19T23:45:43.934Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Fort Worth, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04172441"
    },
    {
      "nct_id": "NCT01227512",
      "title": "Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyponatremia",
        "Dilutional Hyponatremia",
        "Inappropriate ADH Syndrome"
      ],
      "interventions": [
        {
          "name": "tolvaptan",
          "type": "DRUG"
        },
        {
          "name": "Fluid Restriction",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2010-10",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-10-30",
      "last_synced_at": "2026-11-19T23:45:43.934Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Azusa, California + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Banning",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01227512"
    },
    {
      "nct_id": "NCT01025648",
      "title": "Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "E004 (epinephrine inhalation aerosol), 90 mcg/actuation",
          "type": "DRUG"
        },
        {
          "name": "E004 Placebo",
          "type": "DRUG"
        },
        {
          "name": "E004 (epinephrine inhalation aerosol), 125 mcg",
          "type": "DRUG"
        },
        {
          "name": "E004 (epinephrine inhalation aerosol), 220 mcg",
          "type": "DRUG"
        },
        {
          "name": "epinephrine inhalation aerosol, CFC propelled",
          "type": "DRUG"
        },
        {
          "name": "E004 (epinephrine inhalation aerosol), 160 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amphastar Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 9,
      "start_date": "2009-12",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2018-05-16",
      "last_synced_at": "2026-11-19T23:45:43.934Z",
      "location_count": 2,
      "location_summary": "San Jose, California • Stockton, California",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01025648"
    },
    {
      "nct_id": "NCT01024335",
      "title": "Dronabinol Naltrexone Treatment for Opioid Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "injectable naltrexone and dronabinol",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone and placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2010-01",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2018-06-18",
      "last_synced_at": "2026-11-19T23:45:43.934Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01024335"
    },
    {
      "nct_id": "NCT01553058",
      "title": "Vascular Inflammation in Psoriasis Trial (The VIP Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psoriasis",
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Adalimumab (Humira)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "DRUG"
        },
        {
          "name": "NB-UVB phototherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2012-07",
      "completion_date": "2016-10-27",
      "has_results": true,
      "last_update_posted_date": "2018-05-22",
      "last_synced_at": "2026-11-19T23:45:43.934Z",
      "location_count": 9,
      "location_summary": "Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01553058"
    },
    {
      "nct_id": "NCT02274558",
      "title": "A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tardive Dyskinesia"
      ],
      "interventions": [
        {
          "name": "NBI-98854",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 234,
      "start_date": "2014-10",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2017-07-11",
      "last_synced_at": "2026-11-19T23:45:43.934Z",
      "location_count": 48,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Glendale, California + 45 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02274558"
    }
  ]
}